CD20-positive B-cell Lymphoma. Small cell B-cell lymphoma
Conditions
Interventions
Intervention group: Intervention group: In this study, the 177Lu-DOTA-RITUXIMAB PET/CT radiopharmaceutical will be injected intravenously into 10 patients with lymphoma according to the 18F-FDG PET/CT
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma Age greater than 18 years Life expectancy more than 3 months Notpregnant or lactating women Performance status of 2 or better according to the World Health Organization scale. Absolute neutrophil count above1.5 × 109/L, a circulating lymphocyte count below 5 × 109/L, a platelet count above 100 · 109/L, a total bilirubin level of no more than 20 mmol/L, an alanine aminotransferase level below 2.5 times normal, and a serum creatinine clearance level above 60 mL/min. Signed informed consent form
Exclusion criteria
Exclusion criteria: Patients who had previously undergone radiation therapy to the pelvis, femora, or lumbar spine or high-dose treatment with stem cell transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with toxicity. Timepoint: weekly up to week 10 or until recovery from nadir. Method of measurement: Blood chemistry, hematology, and urine analysis.;The proportion of patients who have a partial, stable (not-progressed), or complete response to therapy. Timepoint: 8-12 weeks after treatment. Method of measurement: 18F-FDG PET/CT. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Assadi
Boushehr University of Medical Sciences
Outcome results
None listed